Lung Cancer
News
EBUS Equals Mediastinoscopy for NSCLC Staging
Major Finding: EBUS-TBNA proved similar to mediastinoscopy for lymph node staging of patients with operable NSCLC.
Conference Coverage
Pemetrexed Continuation Maintenance Slows NSCLC Progression
Major Finding: Pemetrexed maintenance therapy plus best supportive care after pemetrexed/cisplatin induction reduced the risk of progression by 38...
News
Pemetrexed Continuation Maintenance Slows NSCLC Progression
Major Finding: Pemetrexed maintenance therapy plus best supportive care after pemetrexed/cisplatin induction reduced the risk of progression by 38...
News
Crizotinib Continues to Produce High Response in ALK+ NSCLC
Major Finding: In an ongoing phase I trial, the overall response rate to crizotinib was 61%, and the median duration of response was 48 weeks.Data...
News
Crizotinib Continues to Produce High Response in ALK+ NSCLC
Major Finding: In an ongoing phase I trial, the overall response rate to crizotinib was 61%, and the median duration of response was 48 weeks.Data...
News
Fewer Side Effects From Proton Therapy in NSCLC
Major Finding: PBT resulted in significantly lower rates of grade 2 or higher esophagitis (P less than .0001), pneumonitis (P less than .002),...
How We Do It
Facilitating Hospice Discussions: A Six-Step Roadmap
News
ASCO, NCCN Recommend EGFR Testing in Advanced Lung Cancer
News
Endobronchial Dysplasia Could Be Marker for Lung Cancer Chemoprevention
Major Finding: Former smokers had an average 0.41-point improvement in biopsy score, an average 1.10-point improvement in their worst baseline...
News
Gene Expression Signatures Predict Erlotinib Sensitivity in NSCLC
Major Finding: Disease control at 8 weeks was 83% in patients with one signature vs. 0% in those without it, and 64% vs.